Chimeric Therapeutics Ltd. (CHM) AI Stock Analysis

Chimeric Therapeutics Ltd. has applied for quotation of 14,814,814 new ordinary fully paid shares on the ASX, with an issue date of September 4, 2026. The securities are being quoted following the exercise of options or conversion of other convertibl...

Chimeric Therapeutics Limited is a biotechnology company focused on cell-based immunotherapies for cancer, including CAR-based programs such as CLTX and CDH-17, and remains in a pre-revenue, development-heavy phase typical of early-stage biotechs. It...

Chimeric Therapeutics has applied to the ASX for quotation of 9,523,809 new ordinary fully paid shares, to be issued on 21 August 2026. The new securities arise from the exercise or conversion of existing options or other convertible instruments, mod...

Chimeric Therapeutics has requested a trading halt on its securities on the ASX, with the pause to remain in place until the earlier of an upcoming material announcement or the resumption of normal trading on 19 August 2026. The halt is tied to pendi...

Chimeric Therapeutics Limited has applied for quotation on the ASX of 1,851,851 new fully paid ordinary shares, with an issue date of 7 August 2026. The new securities arise from the exercise or conversion of existing options or other convertible sec...

Chimeric Therapeutics Ltd. is an Australian cell therapy company developing advanced CAR T and NK cell treatments for solid and blood cancers, with flagship programs targeting gastrointestinal malignancies and acute myeloid leukemia. Its focus on fir...

Chimeric Therapeutics has secured $1.62 million in funding from Endpoints Capital against its anticipated FY26 Research and Development Tax Incentive, providing early access to capital to support Phase 1/2 clinical trial activities and general workin...

Chimeric Therapeutics has issued a disclaimer emphasising that its presentation contains forward-looking statements, highlighting that actual outcomes may differ significantly due to various risks and uncertainties. The company notes potential delays...

Chimeric Therapeutics Limited has applied for quotation of 1,550,387 ordinary fully paid shares on the ASX, to be issued on July 22, 2026. The new securities arise from the exercise of options or conversion of other convertible instruments and will t...

Chimeric Therapeutics Limited has applied for quotation of 1,410,256 new ordinary fully paid shares on the ASX, with an issue date of 14 July 2026. The additional securities, arising from the exercise or conversion of existing instruments, will margi...

Chimeric Therapeutics has notified the market of the cessation of 45,000 listed options, CHMAY, which expired on July 13, 2026 without being exercised or converted. The expiry slightly reduces the company’s pool of potential future equity, but...

Chimeric Therapeutics Limited has announced the cessation of Eric Sullivan as a director, effective 6 July 2026. The company has lodged a Final Director’s Interest Notice with the ASX detailing Sullivan’s remaining interests in company se...

Chimeric Therapeutics announced that independent non-executive director Eric Sullivan has retired from its board, effective immediately, citing personal reasons. Sullivan, who joined the board in August 2023, had served as chairman of the Audit and R...

Chimeric Therapeutics Limited has applied for quotation on the ASX of 1,770,833 new ordinary fully paid shares under its CHM ticker. The securities are scheduled to be issued and quoted on July 2, 2026, expanding the company’s listed share base...